Enlivex Therapeutics to Present at OARSI 2025 World Congress
Ticker: ENLV · Form: 6-K · Filed: Apr 23, 2025 · CIK: 1596812
Sentiment: neutral
Topics: conference-presentation, drug-development, biotech
TL;DR
Enlivex presenting Allocetra data at OARSI 2025, good sign for drug development.
AI Summary
On April 23, 2025, Enlivex Therapeutics Ltd. announced it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 World Congress. These presentations will focus on Allocetra, Enlivex's lead drug candidate, and its potential therapeutic applications.
Why It Matters
The presentation at a major osteoarthritis conference highlights Enlivex's progress and potential for its Allocetra drug candidate in treating inflammatory conditions.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a presentation at a scientific conference, with no immediate financial or operational impact.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Osteoarthritis Research Society International (company) — Conference organizer
- 2025 World Congress (event) — Conference name
- Allocetra (drug_candidate) — Lead drug candidate
FAQ
What is the specific date of the OARSI 2025 World Congress?
The filing does not specify the exact dates of the OARSI 2025 World Congress, only that Enlivex will present during the month of April 2025.
What are the titles of the two poster abstracts Enlivex will present?
The filing does not disclose the specific titles of the two poster abstracts.
What specific therapeutic applications of Allocetra will be discussed?
The filing states the presentations will focus on Allocetra's potential therapeutic applications but does not detail them.
Is this the first time Enlivex is presenting at an OARSI conference?
The filing does not provide information on whether this is Enlivex's first presentation at an OARSI conference.
Where is Enlivex Therapeutics Ltd. headquartered?
Enlivex Therapeutics Ltd. is headquartered at 14 Einstein Street, Nes Ziona, Israel, 7403618.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).